17.4: 5-(2,3-dichlorophenyl)-3-methyl-1-{2-oxo-2-[4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidin-1-yl]-ethyl}-1H-pyrimidine-2,4-dione (compound 17)
Similarly to example 9, starting from 100 mg (0.2 mmol) of 5-bromo-3-methyl-1-{2-oxo-2-[4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidin-1-yl]-ethyl}-1H-pyrimidine-2,4-dione and 58 mg (0.3 mmol) of 2,3-dichlorophenylboronic acid, and after purification by silica gel chromatography eluted with a dichloromethane/methanol 99/1 mixture, 40 mg (35%) of 5-(2,3-dichlorophenyl)-3-methyl-1-{2-oxo-2-[4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidin-1-yl]-ethyl}-1H-pyrimidine-2,4-dione is obtained in the form of a beige solid with a melting point of 170Â° C.